Core Insights - Rani Therapeutics is participating in the Evercore Healthcare Conference on December 3, 2025, with CEO Talat Imran and CFO Svai Sanford presenting [1] - The company focuses on oral delivery of biologics and drugs, aiming to replace traditional injection methods with its proprietary RaniPill capsule technology [2] Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company dedicated to advancing technologies for orally administered biologics and drugs [2] - The RaniPill capsule is a novel, proprietary, and patented platform technology designed to facilitate oral dosing instead of subcutaneous or intravenous methods [2] - The company has successfully conducted multiple preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill capsule technology [2]

Core Insights - Rani Therapeutics is set to present preclinical data on its RaniPill® capsule at ObesityWeek® 2025, highlighting its oral delivery platform for biologics and drugs [1][2] Group 1: Presentation Details - The presentation will focus on the bioequivalence of oral Semaglutide (RT-116) in dogs compared to subcutaneous injections, demonstrating similar weight loss effects [1] - The session will take place on November 6, 2025, from 2:30 pm to 3:30 pm E.T. at the Georgia World Congress Center, with poster number 647 [1] Group 2: Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company dedicated to developing technologies for orally administered biologics and drugs [2] - The RaniPill® capsule is a proprietary and patented platform technology aimed at replacing subcutaneous injections or intravenous infusions with oral dosing [2] - The company has successfully conducted multiple preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill® capsule technology [2]

Core Insights - Rani Therapeutics has appointed two new members, Abe Bassan and Vasudev Bailey, to its Board of Directors, while Andrew Farquharson and Maulik Nanavaty have stepped down [1][2] Group 1: Board Appointments - Abe Bassan is a Partner at Samsara BioCapital, with a background in supporting therapeutics programs and experience in gene therapy [2][3] - Vasudev Bailey, Ph.D., is a General Partner at Anomaly Ventures and has a strong track record in health technology investments, along with experience in cancer detection technology [3] Group 2: Financial Developments - Rani Therapeutics has closed a private placement expected to yield gross proceeds of approximately $60.3 million, led by Samsara BioCapital [4] Group 3: Company Overview - Rani Therapeutics focuses on developing technologies for the oral delivery of biologics and drugs, with its proprietary RaniPill® capsule designed to replace injections with oral dosing [5]

Core Insights - Rani Therapeutics has entered into a significant Collaboration and License Agreement with Chugai Pharmaceutical, valued at up to $1.085 billion, focusing on the development of an oral product utilizing Rani's RaniPill technology and Chugai's antibody for rare diseases [4][5][6] Financial Details - The initial agreement includes a $10 million upfront payment, potential for up to $75 million in technology transfer and development milestones, and up to $100 million in sales milestones, along with single-digit royalties on product sales [5][7] - Rani also completed an oversubscribed private placement financing of $60.3 million, led by Samsara BioCapital and other notable investors [5][8] Strategic Importance - The partnership aims to address unmet medical needs in rare and immunologic diseases by providing oral therapies, which could enhance patient adherence and quality of life compared to traditional injection methods [6][7] - CEO Talat Imran emphasized the collaboration as a convergence of Rani's innovative technology and Chugai's expertise, targeting multiple disease areas with high unmet needs [6][7]

Core Viewpoint - Rani Therapeutics has announced a private placement of Class A common stock and accompanying warrants, expected to generate approximately $60.3 million in gross proceeds, aimed at funding operations into 2028 and advancing its RaniPill® platform [1][3][4] Private Placement Details - The private placement will involve the issuance of 42,633,337 shares of Class A common stock at a price of $0.48 per share and pre-funded warrants at $0.4799 per warrant, with an exercise price of $0.0001 per share for the pre-funded warrants [5] - The accompanying warrants will allow the purchase of up to 125,000,004 shares of Class A common stock at an exercise price of $0.48 per share, exercisable upon stockholder approval [5][6] Use of Proceeds - Net proceeds from the private placement, along with an upfront payment of $10 million and an expected $18 million technology transfer milestone from Chugai Pharmaceuticals, will support the company's operations and pipeline development through 2028 [3][4] Strategic Partnerships - The financing is seen as a pivotal moment for Rani, combining its oral delivery technology with Chugai's expertise in antibody development, aiming to create transformative oral therapies for rare diseases [4][12] Investor Participation - The private placement was led by Samsara BioCapital, with participation from other investors including RA Capital Management and Anomaly, and includes a provision for Samsara and Anomaly to designate board members [6][7][8] Debt Conversion - Avenue Venture Opportunities Fund will convert $6 million of outstanding debt into 12,500,000 shares of Class A common stock and receive warrants on the same terms as other investors, reducing the company's debt obligations [9]

Core Insights - Rani Therapeutics announced the presentation of preclinical data on the RaniPill® capsule at the Endocrine Society's Annual Meeting (ENDO 2025) [1] - The focus of the presentation is on the oral delivery of a bispecific GLP-1/GLP-2 receptor agonist (PG-102) via a robotic pill (RT-114), which achieved bioequivalence to subcutaneous injection in canines [1] Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company that specializes in the oral delivery of biologics and drugs [3] - The company has developed the RaniPill® capsule, a proprietary and patented platform technology aimed at replacing subcutaneous injections or intravenous infusions with oral dosing [3] - Rani has conducted several preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill® capsule technology [3] Presentation Details - The presentation is categorized as a poster presentation under the session titled "Adipose Tissue, Appetite, and Obesity: From Breakthroughs to Real-World Challenges" [2] - The session is scheduled for July 14, 2025, from 12:00 PM to 1:30 PM PT, with the poster number MON-691 [2] - The presenting author is Anvesh Dasari, PhD [2]

Core Insights - Rani Therapeutics announced the presentation of preclinical data on the RaniPill® capsule at the Endocrine Society's Annual Meeting (ENDO 2025) [1][2] - The focus of the presentation is on the oral delivery of a bispecific GLP-1/GLP-2 receptor agonist (PG-102) via a robotic pill (RT-114), which achieved bioequivalence to subcutaneous injection in canines [1] Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company that specializes in the oral delivery of biologics and drugs [3] - The company has developed the RaniPill® capsule, a proprietary and patented platform technology aimed at replacing subcutaneous injections or intravenous infusions with oral dosing [3] - Rani has conducted several preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill® capsule technology [3]

Core Insights - Rani Therapeutics announced promising preclinical data for RT-114, a bispecific GLP-1/GLP-2 receptor agonist, demonstrating bioequivalence to subcutaneous administration when delivered orally via the RaniPill® capsule [1][7] - The company plans to initiate a Phase 1 clinical trial for RT-114 targeting obesity in mid-2025 [4] - Financial results for Q1 2025 show a net loss of $12.7 million, an improvement from a net loss of $14.8 million in Q1 2024 [5][13] Preclinical Developments - Preclinical studies indicated that RT-114 achieved a relative bioavailability of 111% compared to subcutaneously administered PG-102, with similar pharmacokinetic profiles [7] - Successful oral delivery of semaglutide via the RaniPill® capsule was also reported, showing comparable bioavailability and weight loss to subcutaneous administration [7] Financial Performance - As of March 31, 2025, cash, cash equivalents, and marketable securities totaled $15.9 million, down from $27.6 million at the end of 2024 [7] - Contract revenue for Q1 2025 was $0.2 million, a new revenue stream compared to no contract revenue in Q1 2024 [7] - Research and development expenses decreased to $6.6 million from $7.6 million in the same period last year, primarily due to lower compensation costs [7] Company Overview - Rani Therapeutics is focused on the oral delivery of biologics and drugs, utilizing the RaniPill® capsule technology to replace traditional subcutaneous injections [8] - The company aims to make oral biologics a reality for patients, particularly those living with obesity [2]